Citations

Clear

1446 citation(s) found for "Howard, F".

Association of Smoking History With COVID-19 Infection, Hospitalization and Death in the C4R Study
Bowler, R.P., Elkind, Mitchell S, Kaplan, Ronald, Lee, J.S., Ortega, Victor E. , Ramachandran, V., Woodruff, Prescott G. , Balte, Pallavi , Allen, Norrina B. , Barr, R. Graham , Bowler, R.P., Cole, Shelley A. , Couper, David , Cushman, Mary , Demmer, Ryan T. , Doyle, Margaret F. , Howard, Virginia J. , Kanaya, Alka M , Kaplan, R., Phipatanakul, Wanda , Post, Wendy S. , Ramachandran, V., Schwartz, David A. , Tracy, Russell P. , Wenzel, Sally E. , Xanthakis, Vanessa , Oelsner, Elizabeth C.

Mayo Clinic

B14. COVID SEVERITY, OUTCOMES, AND DISPARITIES: FROM MOLECULE TO COMMUNITY | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2752-A2752

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2752 Get It

Memory Performance in Asymptomatic and Prodromal Familial Frontotemporal Lobar Degeneration: Findings from the ALLFTD Consortium (P13-6.001)
Boeve, Bradley, Fields, Julie A. , Syrjanen, Jeremy, Kremers, Walter K. , Staffaroni, Adam M. , Huey, Edward D. , Rascovsky, Katya, Ramos, Marisa, Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard, Kremers, Walter K

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203737 Get It

A Scoping Review of Mobile Apps in Plastic Surgery: Patient Care, Trainee Education, and Professional Development
Jarvis, Nicholas R. , Morris, Bryn E., Verhey, Erik M., Rebecca, Alanna M. , Howard, Michael A., Teven, Chad M. , Jarvis, Tyler

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 13, 2023 | Volume: 11 | Issue: 4 | Pages: e4943

10.1097/gox.0000000000004943 | PMID 37063506 Get It

Background: Over the past 10 years, smartphones have become ubiquitous, and mobile apps serve a seemingly endless number of functions in our everyday lives. These functions have entered the realm of plastic surgery, impacting patient care, education, and delivery of services. This article reviews the current uses of plastic surgery mobile apps, app awareness within the plastic surgery community, and the ethical issues surrounding their use in patient care. Methods: A scoping review of electronically available literature within PubMed, Embase, and Scopus databases was conducted in two waves in November and May 2022. Publications discussing mobile application use in plastic surgery were screened for inclusion. Results: Of the 80 nonduplicate publications retrieved, 20 satisfied the inclusion criteria. Articles acquired from the references of these publications were reviewed and summarized when relevant. The average American Society of Plastic Surgeons evidence rating of the publications was 4.2. Applications could be categorized broadly into three categories: patient care and surgical applications, professional development and education, and marketing and practice development. Conclusions: Mobile apps related to plastic surgery have become an abundant resource for patients, attending surgeons, and trainees. Many help bridge gaps in patient care and surgeon-patient communication, and facilitate marketing and practice development. Others make educational content more accessible to trainees and performance assessment more efficient and equitable. The extent of their impact on patient decision-making and expectations has not been completely elucidated.
Cosmetic Filler and PET Positivity: The Risk of a False Positive
Eitan, Dana , Grunebaum, Lisa D., Howard, Brittany E. , Eitan, Dana N , Grunebaum, Lisa Danielle

Mayo Clinic

The Laryngoscope | March 21, 2023 | Volume: 133 | Issue: 11 | Pages: 2951-2953

10.1002/lary.30667 | PMID 36942944 Get It

ObjectiveTo discuss a case of hyaluronic acid filler displaying as PET avid resulting in a false positive for local recurrence and review of the literature of how filler presents on PET.Study DesignCase report and literature review.MethodsRetrospective case review of a patient with angiosarcoma with PET‐MRI positivity after hyaluronic acid filler injection. Review of the literature was performed.ResultsA 49‐year‐old female with low grade angiosarcoma of the right cheek pT1N0M0 was treated with wide local excision and staged reconstruction with cervicofacial advancement flap with subsequent adjuvant radiation therapy. Surveillance PET/MRI scans were conducted every 3 months. After one year without recurrence, HA injectable filler was offered to correct resultant right facial soft tissue defect. The patient proceeded with HA filler and was counseled on the risk of local increased SUV on imaging. Her PET/MRI 3 months later revealed postsurgical changes in the right premaxillary soft tissues with associated low‐grade hypermetabolism with max SUV 1.8, which elevated from prior max SUV 0.9. Contralateral left maxillary soft tissues revealed max SUV 0.8. Biopsy was initially favored for concern of local recurrence until the potential for filler to be associated with elevated SUV was discussed. Further evaluation with MRI showed diffusely increased T2 signal with some trace enhancement in the region of PET activity, confirming that findings were consistent with HA filler augmentation per the neuroradiologist team.ConclusionsFillers, including hyaluronic acid, are associated with elevated SUV on PET‐CT. Otolaryngologists should be aware of these features to improve patient counseling, avoid unnecessary procedures, and reduce patient anxiety. Laryngoscope, 133:2951–2953, 2023
When Will We Have What We Need to Advise Patients How to Manage Their Carotid Stenosis?: Lessons From SPACE-2
Brott, Thomas G. , Meschia, James F. , Lal, Brajesh K. , Howard, George , Chamorro, Ángel , Howard, Virginia J , Howard, George , Meschia, James F , Howard, Virginia J.

Mayo Clinic

Stroke | March 21, 2023 | Volume: 54 | Issue: 5 | Pages: 1452-1456

10.1161/strokeaha.122.042172 | PMID 36942589 Get It

The recently published SPACE-2 trial (Stent-Supported Percutaneous Angioplasty of the Carotid Artery Versus Endarterectomy-2) compared 3 treatments to prevent stroke in patients with asymptomatic carotid stenosis ≥70%: (1) carotid endarterectomy plus best medical treatment (BMT), (2) transfemoral carotid artery stenting plus BMT, or (3) BMT alone. Because of low enrollment, the findings of similar safety and efficacy for carotid endarterectomy, carotid artery stenting, or BMT alone were inconclusive. Publication of the CREST (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial)-2 results should provide level A evidence that has been lacking for 2 to 3 decades, to guide treatment of asymptomatic patients with severe carotid stenosis. For symptomatic patients with ≥70% stenosis, no trials are underway to update the degree of benefit reported for carotid endarterectomy by NASCET (North American Carotid Endarterectomy Trial) and ECST (European Carotid Surgery Trial), published in 1991. Subsequently, the use of cigarettes has plummeted, and major improvements in medical treatments and in carotid revascularization have emerged. These advances have coincided with abrupt decline in the clinical end points necessary for treatment comparisons in procedural trials. One of the advances in the invasive management of carotid disease has been transcarotid artery revascularization, already with limited approval by the US Food and Drug Administration. Establishing safety and efficacy of transcarotid artery revascularization compared with carotid endarterectomy, carotid artery stenting, or BMT alone may be challenging because of enrollment, regulatory, and funding barriers to design and complete an adequately powered randomized trial.
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Sperger, Jamie M. , Helzer, Kyle T. , Stahlfeld, Charlotte N. , Jiang, Dawei , Singh, Anupama , Kaufmann, Katherine R. , Niles, David J. , Héninger, Erika , Rydzewski, Nicholas R. , Wang, Liguo , Wang, Liewei , Yang, Rendong , Ren, Yanan , Kyriakopoulos, Christos E. , Slovin, Susan F. , Soule, Howard R. , Zhao, Shuang G. , Cai, Weibo , Dehm, Scott M. , Lang, Joshua M. , Engle, Jonathan W , Huang, Peng , Kyriakopoulos, Christos E , Slovin, Susan F , Soule, Howard R , Zhao, Shuang G , Kohli, Manish , Tagawa, Scott T , Cai, Weibo , Dehm, Scott M , Lang, Joshua M , Wang, Liguo , Engle, Jonathan W. , Kohli, Manish , Tagawa, Scott T.

Mayo Clinic

Clinical Cancer Research | March 20, 2023 | Volume: 29 | Issue: 12 | Pages: 2324-2335

10.1158/1078-0432.ccr-22-1305 | PMID 36939530 Get It

Abstract Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane protein identified in prostate cancer and overexpressed in multiple malignancies. TROP-2 is a therapeutic target for antibody–drug conjugates (ADC). Experimental Design: TROP-2 gene (TACSTD2) expression and markers of treatment resistance from prostate biopsies were analyzed using data from four previously curated cohorts of mCRPC (n = 634) and the PROMOTE study (dbGaP accession phs001141.v1.p1, n = 88). EPCAM or TROP-2–positive circulating tumor cells (CTC) were captured from peripheral blood for comparison of protein (n = 15) and gene expression signatures of treatment resistance (n = 40). We assessed the efficacy of TROP-2–targeting agents in a mouse xenograft model generated from prostate cancer cell lines. Results: We demonstrated that TACSTD2 is expressed in mCRPC from luminal and basal tumors but at lower levels in patients with neuroendocrine prostate cancer. Patients previously treated with ARSI showed no significant difference in TACSTD2 expression, whereas patients with detectable AR-V7 expression showed increased expression. We observed that TROP-2 can serve as a cell surface target for isolating CTCs, which may serve as a predictive biomarker for ADCs. We also demonstrated that prostate cancer cell line xenografts can be targeted specifically by labeled anti–TROP-2 agents in vivo. Conclusions: These results support further studies on TROP-2 as a therapeutic and diagnostic target for mCRPC.
Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)
Wong, Annette , Mannix, Carly , Grantham, Jared J. , Allman‐Farinelli, Margaret , Badve, Sunil V. , Boudville, Neil , Byth, Karen , Chan, Jessie S. M., Coulshed, Susan, Edwards, Marie E., Fernando, Mangalee, Foster, Sheryl , Haloob, Imad, Harris, David C.H. , Hill, Julie, Howard, Kirsten , Howell, Martin , Jiang, Simon , Johnson, David W. , Kline, Timothy L. , Kumar, Karthik, Lee, Vincent , Lonergan, Maureen , Mai, Jun, McCloud, Philip , Peduto, Anthony , Rangan, Anna , Roger, Simon D. , Sud, Kamal , Torres, Vicente E. , Vliayuri, Eswari, Rangan, Gopala K. , Torres, Vincent, Torres, Vicente E , Johnson, David W , Howell, Martin , Lee, Vincent W , Rangan, Anna , Chan, Jessie, Erickson, Bradley J. , Hawley, Carmel M.

Mayo Clinic

BMJ Open | March 15, 2023 | Volume: 8 | Issue: 1 | Pages: e018794

10.1136/bmjopen-2017-018794 | PMID 29358433 Get It

Introduction Maintaining fluid intake sufficient to reduce arginine vasopressin (AVP) secretion has been hypothesised to slow kidney cyst growth in autosomal dominant polycystic kidney disease (ADPKD). However, evidence to support this as a clinical practice recommendation is of poor quality. The aim of the present study is to determine the long-term efficacy and safety of prescribed water intake to prevent the progression of height-adjusted total kidney volume (ht-TKV) in patients with chronic kidney disease (stages 1–3) due to ADPKD. Methods and analysis A multicentre, prospective, parallel-group, open-label, randomised controlled trial will be conducted. Patients with ADPKD (n=180; age ≤65 years, estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m 2 ) will be randomised (1:1) to either the control (standard treatment+usual fluid intake) or intervention (standard treatment+prescribed fluid intake) group. Participants in the intervention arm will be prescribed an individualised daily fluid intake to reduce urine osmolality to ≤270 mOsmol/kg, and supported with structured clinic and telephonic dietetic review, self-monitoring of urine-specific gravity, short message service text reminders and internet-based tools. All participants will have 6-monthly follow-up visits, and ht-TKV will be measured by MRI at 0, 18 and 36 months. The primary end point is the annual rate of change in ht-TKV as determined by serial renal MRI in control vs intervention groups, from baseline to 3 years. The secondary end points are differences between the two groups in systemic AVP activity, renal disease (eGFR, blood pressure, renal pain), patient adherence, acceptability and safety. Ethics and dissemination The trial was approved by the Human Research Ethics Committee, Western Sydney Local Health District. The results will inform clinicians, patients and policy-makers regarding the long-term safety, efficacy and feasibility of prescribed fluid intake as an approach to reduce kidney cyst growth in patients with ADPKD. Trial registration number ANZCTR12614001216606.
A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
Karp, Daniel D. , Nordquist, Luke T., Dorff, Tanya B. , Baeck, Johan , O'Donnell, Joseph Francis, Ames, Tyler D. , Yim, Christina Y. , Price, Matthew R. , Scher, Howard I. , Bryce, Alan H. , Tagawa, Scott T. , Rathkopf, Dana E , Adra, Nabil

Mayo Clinic

Journal of Clinical Oncology | March 14, 2023 | Volume: 41 | Issue: 6_suppl | Pages: TPS292-TPS292

10.1200/jco.2023.41.6_suppl.tps292 Get It

TPS292 Background: PT-112 is a novel small I-O molecule currently in development for several cancers. Preclinical studies have shown the robust induction of immunogenic cell death by PT-112, leading to an anti-cancer adaptive immune response. Biodistribution experiments in mice showed PT-112’s partial bone affinity. In two prior phase I studies, late-line metastatic castration-resistant prostate cancer patients (mCRPC pts) were treated with evidence of anti-cancer activity, including tumor volume reductions, improvements in PET and bone scans, PSA and alkaline phosphatase (ALP) reductions, and anecdotal cases of improvement in disease-related pain. This, taken together with the immunogenic and osteotropic properties observed in preclinical work, provided a strong rationale to further explore PT-112 in mCRPC, an immunologically “cold” disease with a high prevalence of bone metastases. Moreover, in an analysis of >6,000 mCRPC pts, circulating tumor cell (CTC) declines (CTC0 and CTC conversions) were correlated with improvements in survival to a greater extent than PSA declines (PSA50) (Heller et al., JCO, 36:6 2017), prompting incorporation of CTC changes as a secondary endpoint. Methods: The primary objective of the study is to define the dose regimen of PT-112 for pivotal study. Pts are randomized to one of three arms, receiving IV PT-112 on 28-day cycles via one hour infusions on (1) Days 1 and 15 at 250 mg/m2, (2) Days 1 and 15 at 360 mg/m2, or (3) Days 1 and 15 of cycle 1 at 360 mg/m2 followed by 250 mg/m2 on Day 15 of subsequent cycles. Key eligibility criteria include radiographically progressive disease at study entry; ≥3 life-prolonging therapies for metastatic disease including 1-2 taxanes, ≥1 new generation anti-androgen therapies, and other drugs FDA approved on the basis of survival; and allowing bone-only metastatic disease. Efficacy assessments comprise disease control rate at 4 months (DCR4) using RECIST and PCWG3 criteria, objective response rate, CTC0 and CTC conversion, PSA50 and ALP reductions. Additionally, T cell receptor sequencing is conducted to characterize treatment-induced changes in T cell fraction and clonal expansions, as a means of generating meaningful supportive data on the immune mechanism of PT-112 monotherapy. A Fleming two-stage design will be used to assess each arm, with a 20% DCR4 as the null hypotheses, requiring ≥6 of 25 pts responding in stage one and ≥14 of 45 in total to reject the null. In addition, other efficacy measures, such as CTC responses, as well as exposure/response and exposure/safety analyses will be applied to characterize the risk/benefit ratio and select the optimal dose regimen for PT-112. As of October 11th, 2022, 38 pts have been enrolled out of a planned maximum of 135. Clinical trial information: NCT02266745 .
Abstract P540: Cardiovascular Disease Risk Factors and Antibody Response to COVID-19 Vaccination: The C4R Study
Sun, Yifei , Cushman, Mary , Styer, Linda M. , Anderson, Michaela R. , Elkind, Mitchell S, Ortega, Victor E. , Woodruff, Prescott G. , Cole, Shelley, Parker, Monica M. , Kim, John S. , Balte, Pallavi , Tracy, Russell P. , Allen, Norrina B. , Schreiner, Pamela J. , Bowler, Russell P. , Schwartz, David A. , Lee, Joyce , Xanthakis, Vanessa , Doyle, Margaret F. , Kanaya, Alka M , Howard, Virginia J. , Mantis, Nicholas J , Barr, R. Graham , Oelsner, Elizabeth C. , Demmer, Ryan T.

Mayo Clinic

Circulation | March 14, 2023 | Volume: 147 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.147.suppl_1.p540 Get It

Background: Adults with cardiovascular co-morbidities and risk factors are at greater risk of severe COVID-19. These same risk factors may also be associated with an attenuated antibody response to COVID-19 vaccines, although studies in diverse, U.S. population-based cohorts have been limited. Methods: The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) conducted a serosurvey for SARS-CoV-2 antibodies via dried blood spot (DBS) in 14 U.S. cohorts. IgG antibodies to SARS-CoV-2 spike subunit 1 (S1) and nucleocapsid (N) were measured from DBS using a semi-quantitative microsphere immunoassay and reported as median fluorescence intensity (MFI). Multivariable adjusted linear models regressed log-transformed anti-S1 MFI on age, sex, race/ethnicity, education attainment, self-reported diabetes, hypertension, cardiovascular disease (CVD), chronic kidney disease, smoking history, body mass index (BMI), asthma, obstructive lung diseases, DBS batch, anti-N MFI, vaccine type, time between vaccine and DBS, and vaccine dose at time of DBS collection. Results are presented as the percent difference in anti-S1 MFI compared with a reference group. Results: There were 6614 vaccinated participants prior to booster regimens and DBS collection (April 2021-July 2022) with 50%, 48%, and 2% of the cohort who received BNT162b2, mRNA-1273, or other vaccines, respectively. The mean (SD) time between vaccination and DBS was 3.8 (1.8) months. Over 10% of the cohort had self-reported a history of diabetes, 55% had hypertension, and 74% had a BMI>25 kg/m 2 . Anti-S1 MFI decreased as the time between vaccine dose and DBS collection increased. Diabetes was associated with a 16.1% lower anti-S1 MFI (95%CI:-22.4,-9.5) whereas neither hypertension (-3.8%;95%CI:-9.3,2.1), nor cardiovascular disease history (-5.3%;95%CI:-16.3,7.4) were associated with anti-S1 MFI. Former and current smoking history were each associated with a lower anti-S1 MFI: (-6.6%;95%CI:-12.1,-0.8) and (-16.1%;95%CI:-24.7,-6.6), respectively. Participants with a BMI 25-29.9 kg/m 2 had a 7.6% higher anti-S1 MFI (95%CI:0.3,15.4) whereas those with a BMI of 30-35 kg/m 2 and >35 kg/m 2 had 6.2% (95%CI:-2.4,15.5) higher and 8.9% lower (95%CI:-17.6,0.7) MFI levels, respectively. Older age and male sex were each associated with a lower anti-S1 MFI and mRNA-1273 vaccine, Asian subgroup, higher anti-N titer, and prior COVID-19 infection were each associated with higher anti-S1 MFI. Chronic kidney disease, education attainment, and lung disease were not associated with anti-S1 MFI. Conclusions: Several traditional cardiovascular disease risk factors were associated with diminished humoral responses to the initial COVID-19 vaccine regimens in a diverse U.S. population-based cohort and may have implications on strategies to improve vaccine responses.